HDAC4 nucleic acid administration to treat retinal disease
AssigneePresident and Fellows of Harvard College
InventorsConstance L. Cepko, Bo Chen
Life of this patent
Estimating the term…
Abstract
Methods for inhibiting retinal cell death by altering expression of one or more of HDAC4, HDAC5, HDAC6, HDAC7, and HIF1α in a retinal cell are provided.
Claims20
A method of inhibiting death of a retinal cell compromised by a neurodegenerative eye disorder, comprising administering to the retina of a subject having the neurodegenerative eye disorder an isolated HDAC4 nucleic acid molecule, thereby inhibiting death of the retinal cell.
A method for treating or preventing a neurodegenerative eye disorder in a subject, comprising administering to the retina of said subject an isolated HDAC4 nucleic acid molecule, thereby treating or preventing said neurodegenerative eye disorder in said subject.
A method of inhibiting death of an isolated retinal cell compromised by a neurodegenerative eye disorder, comprising contacting said isolated retinal cell with an isolated HDAC4 nucleic acid molecule, thereby inhibiting death of the isolated retinal cell.
A method of inhibiting death of a bipolar cell in a subject, comprising administering to the retina of said subject an isolated HDAC6 nucleic acid molecule, thereby inhibiting death of said bipolar cell.
A method of inhibiting death of an isolated bipolar cell, comprising contacting said isolated bipolar cell with an isolated HDAC6 nucleic acid molecule, thereby inhibiting death of said bipolar cell.
Dependencies are inferred from the claim text.